David Hamilton at VentureBeat: Life Sciences recently wrote about the potential business plans of two popular genomic companies – Navigenics and 23andMe. It appears that the post was motivated by the recent article in Portfolio. David writes:
“Over the last few months, startups like 23andMe and Navigenics have attracted a fair bit of attention for promising to let ordinary people search through their own genomes to better understand their disease risk, genealogy and ancestry. One of the first major efforts to figure them out, however â€” courtesy of the November issue of Portfolio â€” left me with the distinct impression that these companies may not actually be anywhere near as revolutionary as they seem.”
There’s some discussion in the comment section, and David presents a number of links to the many previous articles he’s written about 23andMe and Navigenics.